Summary
The provided FDA label excerpts do not support most of the AI claims regarding indication scope, HPV low- vs high-risk types, wart morphology, onset of benefit, specific trial response percentages, mechanism of immune attack, or dosing/usage timing beyond the 16-week limit. Several safety/population statements (e.g., weakened immune system, pregnancy, severe irritation/open infection) are not supported or are unsupported as stated by the excerpts.
Category Scores
Accurate Statements
Veregen (resiquimod) is a topical cream used to treat certain types of warts.
Not supported: label excerpt provided is for Veregen (sinecatechins) ointment 15% and indication for external genital and perianal warts in immunocompetent patients 18 years and older.
Veregen is available by prescription only.
Unsupported: no prescription-only statement is present in the provided label excerpts.
Unsupported Statements
Veregen (resiquimod) is a topical cream used to treat certain types of warts.
Label excerpt identifies Veregen as sinecatechins ointment 15% and indicates external genital and perianal warts in immunocompetent patients 18 years and older; AI claim uses the wrong active ingredient (resiquimod) and is not limited to the labeled site/population.
Veregen is available by prescription only.
Not supported by any provided excerpt.
Veregen contains resiquimod, a toll-like receptor 7 (TLR 7) and toll-like receptor 8 (TLR 8) agonist.
Not supported; provided label describes sinecatechins (green tea extract catechin mixture) and states mechanism of action is unknown. No TLR7/TLR8 agonism or resiquimod is mentioned.
Veregen works by stimulating the body's immune system to recognize and attack human papillomavirus (HPV) that causes warts.
Contrary to label excerpt: mechanism of action involved in clearance is unknown.
Veregen can help reduce the appearance of warts.
Partially/implicitly consistent with treating warts, but not supported as phrased in the provided excerpts; indication wording is specific to topical treatment of external genital and perianal warts.
Veregen can help promote a more even skin texture.
Not supported by any provided label excerpt (no cosmetic/skin-texture claim).
Veregen is specifically approved to treat certain types of warts that appear on the face and hands.
Contradiction with provided indication excerpt: labeled for external genital and perianal warts in immunocompetent patients 18 years and older; face/hands not mentioned.
The treated wart types are caused by low-risk HPV types.
Not supported; no HPV risk-type classification is included in provided excerpts.
The treated wart types are typically small and superficial.
Not supported; no wart size/depth description is included in provided excerpts.
Veregen may not be effective against all types of warts, including those caused by high-risk HPV types.
Not supported; no effectiveness limitations by HPV risk type are present in provided excerpts.
Veregen may not be effective against warts that are deep or thick.
Not supported; no depth/thickness effectiveness limitations are present in provided excerpts.
Veregen can start to show results within 3 months of treatment.
Not supported as a specific onset statement; label excerpts provide median time to complete clearance of 10 weeks and 16 weeks, but do not state 'within 3 months' as an onset claim.
In a clinical trial, up to 44% of patients experienced a reduction in wart size after 3 months of treatment.
Not supported by provided clinical study excerpts; no '44%' or 'reduction in wart size' endpoint is present. Label excerpt defines response as complete clinical visual clearance by week 16.
Common side effects of Veregen include redness at the application site.
Not explicitly supported as 'common side effects' in the provided excerpt; label does mention local skin reactions such as erythema as frequent, but does not list 'redness at application site' as a common side effect in a typical frequency statement.
Common side effects of Veregen include itching at the application site.
The provided adverse events list includes pruritus as part of discontinuation events; the excerpt does not establish it as a 'common' side effect.
Common side effects of Veregen include swelling at the application site.
Not supported by provided excerpts; adverse event examples listed include erythema, vesicles, erosion/ulceration, pain, hypersensitivity, pruritus, etc., but 'swelling' is not mentioned.
Redness, itching, and swelling at the application site are usually mild and temporary.
Not supported by provided excerpts; label excerpt mentions severity thresholds for continuing therapy but does not characterize redness/itching/swelling as mild and temporary.
Severe skin irritation is a reason not to use Veregen.
Not supported by provided excerpts. Label excerpt states treatment should be continued when severity of local skin reaction is acceptable; no rule that 'severe skin irritation' is a contraindication/reason not to use is provided.
An active skin infection is a reason not to use Veregen.
Not supported by provided excerpts; label excerpt mentions superinfection of warts and ulcers as an event leading to discontinuation or dose interruption, but does not state a contraindication to use with active skin infection.
Veregen is not suitable for everyone.
Too general; not supported in provided excerpts as a specific safety suitability statement.
People with a weakened immune system should talk to a doctor before using Veregen.
Label excerpt: safety/effectiveness in immunosuppressed patients has not been established; it does not state 'should talk to a doctor before using' in the provided text.
Pregnant or breastfeeding people should talk to a doctor before using Veregen.
Not supported as stated; label excerpt says no available data on pregnancy to evaluate risk, and lactation data are limited but does not provide a 'talk to a doctor' instruction in the provided text.
People taking certain medications should talk to a doctor before using Veregen.
No drug interaction information is included in the provided label excerpts; cannot be supported.
Contradictions
Low
AI Statement
Veregen is specifically approved to treat certain types of warts that appear on the face and hands.
Label Reference
Indication excerpt: Veregen indicated for topical treatment of external genital and perianal warts in immunocompetent patients 18 years and older (Section 1.1).
Low
AI Statement
Veregen contains resiquimod, a toll-like receptor 7 (TLR 7) and toll-like receptor 8 (TLR 8) agonist.
Label Reference
Description excerpt: sinecatechins (botanical green tea catechins mixture); Mechanism of action involved in clearance is unknown (Sections 11 and 12.1).
Low
AI Statement
Veregen works by stimulating the body's immune system to recognize and attack human papillomavirus (HPV) that causes warts.
Label Reference
Mechanism of action excerpt: mode of action involved in clearance ... is unknown (Section 12.1).
Important Omissions
FDA-labeled indication limits to external genital and perianal warts (Condylomata acuminata) in immunocompetent patients ≥18 years; not mentioned/incorrectly broadened by the AI claims (face/hands).
Importance:
High
Limitations of use: safety/effectiveness not established beyond 16 weeks or multiple treatment courses.
Importance:
Moderate
Safety and effectiveness not established in immunosuppressed patients (and use of Veregen not established for other anatomical HPV diseases such as urethral, intra-vaginal, cervical, rectal, intra-anal).
Importance:
Moderate
Administration details: apply three times daily; apply about 0.5 cm strand per wart; thin layer; wash hands before/after; do not wash off before next application; avoid ophthalmic/oral/intravaginal/intra-anal use.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The AI claims substantially misstate the active ingredient/mechanism and incorrectly expand labeled indication to face/hands. Multiple other claims about HPV risk types, wart characteristics, effectiveness timing, and safety counseling are unsupported or not present in the provided label excerpts, increasing the likelihood of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Incorrect indication scope (face/hands) and incorrect active ingredient/mechanism (resiquimod/TLR7/8/immune attack), plus numerous unsupported efficacy and safety statements not present in the provided label excerpts.
Suggested Improvement
Restrict claims to the provided FDA-labeled indication (external genital and perianal warts in immunocompetent patients ≥18 years), correct the drug identity (sinecatechins ointment 15%), avoid asserting an unknown mechanism, and only state efficacy/safety outcomes that appear in the label excerpts (e.g., trial endpoints and labeled limitations such as treatment no longer than 16 weeks).